Amicus Therapeutics, Inc.
FOLD
$9.89
$0.111.07%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 169.06M | 154.69M | 125.25M | 149.71M | 141.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 169.06M | 154.69M | 125.25M | 149.71M | 141.52M |
| Cost of Revenue | 19.47M | 15.22M | 11.70M | 14.84M | 13.28M |
| Gross Profit | 149.59M | 139.47M | 113.55M | 134.87M | 128.24M |
| SG&A Expenses | 90.04M | 84.54M | 91.83M | 86.67M | 75.11M |
| Depreciation & Amortization | 1.87M | 1.85M | 1.84M | 2.04M | 2.17M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 134.79M | 162.46M | 133.20M | 133.74M | 116.72M |
| Operating Income | 34.27M | -7.77M | -7.95M | 15.97M | 24.80M |
| Income Before Tax | 34.27M | -19.18M | -18.05M | 7.93M | 6.79M |
| Income Tax Expenses | 16.97M | 5.24M | 3.64M | -6.81M | 13.51M |
| Earnings from Continuing Operations | 17.31M | -24.42M | -21.69M | 14.74M | -6.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.31M | -24.42M | -21.69M | 14.74M | -6.73M |
| EBIT | 34.27M | -7.77M | -7.95M | 15.97M | 24.80M |
| EBITDA | 36.14M | -5.92M | -6.12M | 18.01M | 26.97M |
| EPS Basic | 0.06 | -0.08 | -0.07 | 0.05 | -0.02 |
| Normalized Basic EPS | 0.07 | -0.04 | -0.04 | 0.02 | 0.02 |
| EPS Diluted | 0.06 | -0.08 | -0.07 | 0.05 | -0.02 |
| Normalized Diluted EPS | 0.07 | -0.04 | -0.04 | 0.02 | 0.02 |
| Average Basic Shares Outstanding | 308.47M | 308.25M | 307.69M | 306.14M | 304.69M |
| Average Diluted Shares Outstanding | 310.43M | 308.25M | 307.69M | 306.14M | 304.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |